PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

BACKGROUND: Clinical trials of immune checkpoints modulators, including both programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors, have recently shown promising activity and tolerable toxicity in pre-treated NSCLC patients. However the predictive role of PD-L1 express...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Passiglia, Francesco, Bronte, Giuseppe, Bazan, Viviana, Natoli, Clara, Rizzo, Sergio, Galvano, Antonio, Listì, Angela, Cicero, Giuseppe, Rolfo, Christian, Santini, Daniele, Russo, Antonio
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2016
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4991415/
https://ncbi.nlm.nih.gov/pubmed/26918451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7582
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk